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An elderly male with dementia was admitted for increasing aggression and agitation. He was initially
treated with risperidone, citalopram, and memantine, as well as nonpharmacological interventions such
as behavioral approaches, environmental modiﬁcations, and maintaining sleep routines without
improvement. He was treated with the addition of the alpha-1 adrenoreceptor antagonist prazosin, with
a subsequent reduction in the number of doses of antipsychotic medication needed to maintain
appropriate behavior. Prazosin was well tolerated in this patient who had a signiﬁcant history of heart
disease and poor systolic function. Prazosin may represent a relatively safe and effective medication for
the treatment of agitation and aggression in patients with dementia, including patients with comorbid
cardiac conditions. In this patient, prazosin was better tolerated than the other medications utilized.
Copyright © 2015, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Aggressive behaviors in dementia and Alzheimer's disease (AD)
are prevalent, with estimates of physical aggression ranging be-
tween 11% and 46% of AD patients within the community and up to
42% of nursing home residents.1 Behavioral symptoms such as
these are of great importance to family and caregivers as these tend
to be the most distressing and are responsible for many patients
requiring nursing home placement.2 Currently, there is very limited
efﬁcacy for the most commonly used drugs for aggression and
agitation.3 The following case report describes the successful use of
the medication prazosin for agitation and aggression in an elderly
male patient with dementia and comorbid heart failure.
2. Case Report
An 83 year old Filipino male with dementia was admitted to a
psychiatric ward following aggressive behavior at a residential
nursing facility. His diagnosis was established as major neuro-
cognitive disorder withmultiple etiologies, mixed vascular, and AD,sychiatry, Tripler Army Med-
USA.
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inical Gerontology & Geriatrics. Pub
d/4.0/).although he had carried the diagnosis of “dementia not otherwise
speciﬁed” for several years prior to presentation. He had been fol-
lowed by his primary care provider for this condition and his other
comorbid medical conditions until he was referred to a geriatrician.
The patient had both cognitive and behavioral symptoms, namely
agitation, secondary to his dementia. He had spent almost a year in
a nursing home. During his time at the nursing home, he was noted
to be frequently disoriented, restless, and difﬁcult to redirect. He
was noted by staff to be agitated at times and would often become
aggressive with care providers and other residents, yelling at them
and raising his ﬁsts to them in a threatening manner.
Treatment prior to admission for his aggressive behavior was
risperidone 2 mg twice per day, citalopram 10 mg daily, and
memantine 10 mg daily concurrently, without signiﬁcant
improvement in his behavior. His behavioral disturbances
continued and subsequently he was admitted to the psychiatric
ward following an episode of physical aggression with staff.
Pertinent medical problems included congestive heart failure
with low estimated ejection fraction, persistent asymptomatic
bradycardia, hypertension, chronic kidney disease, and hearing
impairment. According to family and prior medical records, he had
developed signiﬁcant cognitive deﬁcits with a noticeable but slow
stepwise progression resulting in his current state of intermittent
disorientation and poor memory at baseline. His neurocognitivelished by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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versus AD. The patient's behavior eventually became more
disruptive over time, with increased levels of agitation and
aggression, making it difﬁcult for his wife to care for him at home
and he was eventually admitted to a long term nursing facility.
Upon admission to the psychiatric ward, he was initially
restarted on his previously prescribed outpatient medications. A
mental status exam revealed a thin, elderly Filipino male with
psychomotor agitation in the form of restlessness, normal speech
with accent present, mood “okay” and affect full range with mild
lability (from pleasant to irritable and angry at times). He was
mostly uncooperative with the interview. He exhibited persevera-
tion and tangentiality. He lacked insight and judgment was poor.
His cognitive exam was signiﬁcant for poor attention, concentra-
tion, and poorly oriented to place and time. Memory and intellec-
tual functioning were difﬁcult to assess given his agitation and
inability to cooperate.
Medical causes of delirium were ruled out (i.e., infection,
metabolic disturbance, urinary retention/obstruction), although
concern remained about polypharmacy as a potential exacerbating
factor. For the treatment of his agitation, he was initially continued
on his outpatient psychotropic medications and one to one care
was initiated. He remained agitated and aggressive with staff and
required several additional as needed doses of risperidone 0.5 mg
over the ﬁrst 2 weeks. He was eventually switched from risperi-
done to scheduled haloperidol 0.5 mg twice per day. Benzodiaze-
pines and anticholinergics were avoided to prevent worsening
confusion or sedation. Citalopram and memantine were dis-
continued due to concerns that these medications were having
activating effects.
Several nonpharmacological interventions were initiated,
including continuous one to one interactions, behavioral ap-
proaches, environmental modiﬁcation, and exercise. These in-
terventions were minimally beneﬁcial and his behavior continued
to worsen. Attempts were made to communicate with the patient
in his preferred language (Tagalog), but this was also ineffective. He
exhibited agitation and verbal aggression throughout the day with
increased restlessness at night. He was observed frequently dis-
robing, yelling at staff, and resisting efforts from his care providers.
There were several incidents where he became physically violent
with staff (slapping, pushing), although no one was ever harmed.
The patient's aggressive behavior persisted despite further ad-
justments to his scheduled antipsychotics (i.e., changing to olan-
zapine 1.25 mg twice per day and then increasing his bedtime
dosage of olanzapine to 2.5 mg). Additional doses of olanzapine
1.25 mg given on an as needed basis were also ineffective at
managing his behavior. The resulting increase in cumulative doses
of olanzapine did not result in extra pyramidal symptoms or
motoric dysfunction such as Parkinsonism, or tardive dyskinesia.
However, he did continue to have restlessness and a persistent
need to get out of bed and walk, even during nighttime hours. Due
to concerns for akathisia as a possible cause of this restlessness, his
dose of scheduled olanzapine was lowered and limits were placed
on the cumulative daily dose he was allowed to receive.
Despite the interventions initiated, the patient continued to
display aggressive behavior with staff and his family. A review of
the literature on alternative pharmacological approaches to treat-
ing agitation in dementia identiﬁed an article describing prazosin
as a possible effective treatment.4 The patient was started on pra-
zosin at 1 mg nightly and his dose was increased 1 mg every 2e3
days to a ﬁnal dosage of 6 mg at bedtime. One week after initiating
treatment (at a dose of 3 mg nightly), nursing staff began to note
improvement in his behavior, speciﬁcally less aggression and
agitation. He began to require fewer doses of as needed olanzapine
for agitation during both day and night. He also began to haveincreased hours of sleep and less restlessness at nighttime. Two
weeks after the addition of prazosin (at 5 mg nightly), the patient's
observed behavior was signiﬁcantly improved according to both
nursing staff and his family. He did continue to receive additional
doses of olanzapine as needed for subjective “restlessness” per the
nursing staff report, but this was signiﬁcantly less frequent than
prior to initiating prazosin.
The patient was monitored closely for medical complications in
the setting of signiﬁcant cardiac dysfunction. Despite his medical
comorbidities, he tolerated the addition of prazosin well, with only
minimal periods of measured hypotension. He remained asymp-
tomatic during these periods and did not have any reported epi-
sodes of postural hypotension, dizziness, or syncope. He remained
medically stable throughout his treatment. He had no reported
physical violence for 4 weeks following the initiation of prazosin
and remained compliant with his care during this period of time.
His mental status exam improved with less psychomotor agitation,
improved ability to attend to interview, and less tangential thought.
His cognitive testing remained stable with deﬁcits in memory and
orientation.
In addition, his wife and family noted a signiﬁcant improvement
during their interactions with him and did not report any aggres-
sive behavior or agitation during multiple encounters. Following
this period of observation, the patient was eventually re-evaluated
and placed back at another nursing home. Three months later, he
continued to tolerate prazosin well and he was not noted to have
signiﬁcant aggressive behavior.
3. Discussion
The recent study by Wang et al4 posits that the efﬁcacy of the
alpha-1 adrenoreceptor antagonist prazosin lies in its ability to
prevent overstimulation of compensatory norepinephrine path-
ways associated with aggression and agitation in the brains of AD
patients. Prazosin is an antihypertensive that has also been suc-
cessfully used in treating sleep disturbance related to post-
traumatic stress disorder. It is selective for alpha-1 receptors and
may help to reduce the adrenergic response associated with
agitation and aggression. Atypical antipsychotics currently remain
the most useful and well known pharmacological intervention for
agitation, but these drugs carry signiﬁcant risks with recent evi-
dence suggesting increased risk of mortality in the elderly.5 Recent
data from studies of cholinesterase inhibitors suggest that theymay
not be efﬁcacious in acute agitation.6 N-methyl-D-aspartate recep-
tor antagonists such as memantine may offer some beneﬁt in mild
to moderate agitation or aggression according to current data.7
Serotonin-speciﬁc reuptake inhibitors such as citalopram have
been tried for the treatment of agitation with similar efﬁcacy as
risperidone.8 However, these studies are small and need to be
replicated. Our patient was tried on both memantine and cit-
alopram with no response.
In summary, prazosin was well tolerated in this elderly male
patient with dementia and multiple medical problems, including
signiﬁcantly reduced systolic function and chronic bradycardia. The
addition of prazosin resulted in clinically signiﬁcant reductions in
agitation, aggressive behaviors, and physical violence as observed
by the team. The patient did continue to receive low doses of
antipsychotic medications scheduled and as needed, but the clini-
cally observed change in behavior did not occur until after the
addition of prazosin. Consideration was given to a possible
resolving delirium or akathisia in this patient, resulting in
improvement of behavior. However, his stable cognition and the
time course of long standing behavioral symptoms make this an
unlikely explanation. It was felt that his pre-existing neuro-
cognitive disorder better accounted for his behavioral disturbances.
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excluded, although the course of his clinical improvement coin-
cided with the initiation and maintenance of treatment with
prazosin.
Although the current data is limited, it may be that alpha-1
adrenoreceptor antagonists represent a useful and inexpensive
alternative to the currently available medications. Although there
remains concerns regarding use of this medication in patients with
comorbid cardiac dysfunction, this patient tolerated themedication
without signiﬁcant side effects. Clinicians must, however, weigh
the risks and beneﬁts in patients on an individual basis. There were
a low number of patients with reported postural hypotension in the
study by Wang et al.4 Larger scale, randomized, placebo controlled
trials will need to be done to verify the ﬁndings by Wang et al.4
Currently such trials have been initiated and are ongoing.Conﬂicts of interest
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